Ibnsina Pharma (EGX:ISPH)
Egypt · Delayed Price · Currency is EGP 12.51
+0.36 (2.96%)
At close: Jun 4, 2026
Ibnsina Pharma Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 80,053 | 76,597 | 55,842 | 33,949 | 22,264 | 21,733 | |
Revenue Growth (YoY) | 28.47% | 37.17% | 64.49% | 52.48% | 2.45% | 16.35% |
Cost of Revenue | 73,392 | 70,148 | 51,446 | 31,434 | 20,648 | 20,103 |
Gross Profit | 6,661 | 6,449 | 4,397 | 2,515 | 1,617 | 1,630 |
Selling, General & Admin | 3,004 | 2,681 | 1,931 | 1,289 | 1,076 | 829.22 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 2.75 |
Other Operating Expenses | -10.27 | -10.93 | -7.39 | -9.46 | -7 | - |
Operating Expenses | 3,213 | 2,907 | 2,139 | 1,364 | 1,135 | 962.17 |
Operating Income | 3,448 | 3,542 | 2,258 | 1,152 | 482.22 | 667.35 |
Interest Expense | -2,420 | -2,559 | -1,686 | -1,044 | -477.09 | -284.18 |
Interest & Investment Income | - | 0.18 | 0.2 | - | - | - |
Currency Exchange Gain (Loss) | 50.66 | 4.67 | 55.35 | 38.53 | 38.41 | 0.28 |
Other Non Operating Income (Expenses) | 17.49 | 17.49 | 71.67 | 121.65 | 131.01 | 86.01 |
EBT Excluding Unusual Items | 1,096 | 1,006 | 698.45 | 267.75 | 174.55 | 469.46 |
Gain (Loss) on Sale of Investments | - | - | 1.88 | -1.13 | - | - |
Gain (Loss) on Sale of Assets | 71.51 | 71.51 | 2.95 | 1.39 | 0.75 | 4.25 |
Legal Settlements | - | - | - | - | - | -48 |
Other Unusual Items | - | - | - | - | - | -0.37 |
Pretax Income | 1,168 | 1,077 | 703.28 | 268.02 | 175.31 | 425.34 |
Income Tax Expense | 141.8 | 125.36 | 88.72 | 54.74 | 4.43 | 110.95 |
Earnings From Continuing Operations | 1,026 | 951.98 | 614.56 | 213.27 | 170.87 | 314.4 |
Minority Interest in Earnings | 0 | -0 | 0 | 0.39 | 1.71 | 0.33 |
Net Income | 1,026 | 951.98 | 614.56 | 213.66 | 172.58 | 314.73 |
Preferred Dividends & Other Adjustments | 194.95 | 180.88 | 116.77 | 40.52 | 36.95 | 28.4 |
Net Income to Common | 831.09 | 771.11 | 497.8 | 173.14 | 135.63 | 286.33 |
Net Income Growth | 46.93% | 54.90% | 187.63% | 23.80% | -45.16% | 40.09% |
Shares Outstanding (Basic) | 1,008 | 1,008 | 1,008 | 1,008 | 1,008 | 1,302 |
Shares Outstanding (Diluted) | 1,008 | 1,008 | 1,008 | 1,008 | 1,008 | 1,302 |
Shares Change (YoY) | - | - | - | - | -22.58% | 16.25% |
EPS (Basic) | 0.82 | 0.76 | 0.49 | 0.17 | 0.13 | 0.22 |
EPS (Diluted) | 0.82 | 0.76 | 0.49 | 0.17 | 0.13 | 0.22 |
EPS Growth | 46.93% | 54.90% | 187.51% | 27.65% | -38.81% | 33.78% |
Free Cash Flow | 923.88 | -805.66 | -1,187 | -228.23 | -436.58 | -487.96 |
Free Cash Flow Per Share | 0.92 | -0.80 | -1.18 | -0.23 | -0.43 | -0.38 |
Dividend Per Share | - | - | 0.160 | - | - | 0.086 |
Gross Margin | 8.32% | 8.42% | 7.87% | 7.41% | 7.26% | 7.50% |
Operating Margin | 4.31% | 4.62% | 4.04% | 3.39% | 2.17% | 3.07% |
Profit Margin | 1.04% | 1.01% | 0.89% | 0.51% | 0.61% | 1.32% |
Free Cash Flow Margin | 1.15% | -1.05% | -2.13% | -0.67% | -1.96% | -2.25% |
EBITDA | 3,628 | 3,714 | 2,391 | 1,266 | 596.27 | 784.78 |
EBITDA Margin | 4.53% | 4.85% | 4.28% | 3.73% | 2.68% | 3.61% |
D&A For EBITDA | 179.53 | 171.77 | 133.16 | 114.18 | 114.04 | 117.43 |
EBIT | 3,448 | 3,542 | 2,258 | 1,152 | 482.22 | 667.35 |
EBIT Margin | 4.31% | 4.62% | 4.04% | 3.39% | 2.17% | 3.07% |
Effective Tax Rate | 12.14% | 11.64% | 12.62% | 20.42% | 2.53% | 26.08% |